SCHEMBL464919

SCHEMBL464919

CC(=O)N(CC(=O)NCc1ccccc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.57
HDAC6 Q9UBN7 1/20 0.57
GAA P10253 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
HSP90AA1 P07900 1/20 0.49
ALDH1A1 P00352 2/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 2/20 0.48
EPHX2 P34913 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
MCL1 Q07820 1/20 0.47
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4793278 0.87 HDAC1 (0.60) HDAC1HDAC6GAAL3MBTL1KMT2A
SCHEMBL9155475 0.82 HDAC1 (0.62) HDAC1HDAC6GAAL3MBTL1KMT2A
SCHEMBL8837264 0.80 HDAC1 (0.51) HDAC1HDAC6GAAL3MBTL1KMT2A
SCHEMBL219829 0.80 ALDH1A1 (0.47) HDAC1HDAC6L3MBTL1KMT2AMEN1
SCHEMBL11667796 0.79 ALDH1A1 (0.46) L3MBTL1KMT2AMEN1ALDH1A1GLA
SCHEMBL7144694 0.78 GAA (0.59) GAAL3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL10536972 0.78 KMT2A (0.50) GAAKMT2AMEN1ALDH1A1HPGD
SCHEMBL13645008 0.76 GAA (0.53) HDAC1HDAC6GAAL3MBTL1KMT2A
SCHEMBL690247 0.76 ALDH1A1 (0.53) L3MBTL1KMT2AMEN1ALDH1A1GLA
SCHEMBL11557648 0.76 ALDH1A1 (0.53) L3MBTL1KMT2AMEN1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046386-B1 PEPTIDE COMPOUNDS FOR THE TREATMENT OF SKELETAL MUSCLE DISORDERS ASSOCIATED WITH ION CHANNEL DYSFUNCTION UCB PHARMA GMBH (DE) 2014-07-23 EP claimed
US-20140128377-A1 METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES UCB PHARMA GMBH (DE) 2014-05-08 US claimed
US-20130316953-A1 NEW USES FOR AMINO ACID ANTICONVULSANTS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2013-11-28 US claimed
EP-2210598-B1 Anticonvulsant amino acids for the treatment of pain RES CORP TECHNOLOGIES INC (US) 2013-09-18 EP claimed
US-8519183-B2 Uses for amino acid anticonvulsants RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2013-08-27 US claimed
EP-1753415-B1 NOVEL USE OF PEPTIDE COMPOUNDS FOR TREATING PAIN IN TRIGEMINAL NEURALGIA UCB PHARMA GMBH (DE) 2013-04-17 EP claimed
US-20100273716-A1 NEW USES FOR AMINO ACID ANTICONVULSANTS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2010-10-28 US claimed
US-20100273714-A1 PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS SCHWARZ PHARMA AG (DE) 2010-10-28 US claimed
US-20100260716-A1 COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS UCB PHARMA GMBH (DE) 2010-10-14 US claimed
EP-1695703-B1 Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis RES CORP TECHNOLOGIES INC (US) 2010-08-11 EP claimed
EP-1373300-A2 NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN SCHWARZ PHARMA AG (DE) 2004-01-02 EP claimed
EP-1365787-A2 NEW USES FOR AMINO ACID ANTICONVULSANTS FOR TREATMENT OF PAIN Research Corporation Technologies, Inc (US) 2003-12-03 EP claimed
US-20030171300-A1 Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary UCB PHARMA GMBH (DE) 2003-09-11 US claimed
WO-2002074784-A2 NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN SCHWARZ PHARMA AG (DE) 2002-09-26 WO claimed
EP-1243262-A1 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain SCHWARZ PHARMA AG (DE) 2002-09-25 EP claimed
US-20020086828-A1 Uses for amino acid anticonvulsants HARRIS ROBERT H (US) 2002-07-04 US claimed
WO-2002015922-A2 NEW USES FOR AMINO ACID ANTICONVULSANTS FOR TREATMENT OF PAIN RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2002-02-28 WO claimed
US-5378729-A Diamide derivatives RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-01-03 US claimed
EP-0194464-B1 AMINO ACID DERIVATIVES AND USE THEREOF FOR THE PREPARATION OF AN ANTICONVULSANT Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1991-04-03 EP claimed
EP-0194464-A1 Amino acid derivatives and use thereof for the preparation of an anticonvulsant Research Corporation Technologies, Inc. (a Delaware corp.) (US) 1986-09-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086828-A1 Uses for amino acid anticonvulsants SLC1A2, SLC1A1, SLC1A3 HDAC1 1291/4885HDAC6 972/4885GAA 1506/4885
US-20100273714-A1 PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS VIP, VGF, PRSS12 HDAC1 362/4885HDAC6 389/4885GAA 2774/4885
US-20130316953-A1 NEW USES FOR AMINO ACID ANTICONVULSANTS SLC1A2, SLC1A1, SLC1A3 HDAC1 1427/4885HDAC6 900/4885GAA 2331/4885
US-20140128377-A1 METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES GABRE, GRIK2, GABRR1 HDAC1 463/4885HDAC6 213/4885GAA 2215/4885
US-20030171300-A1 Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary OPRK1, OPRL1, PTGER1 HDAC1 1676/4885HDAC6 1360/4885GAA 4419/4885
US-20100273716-A1 NEW USES FOR AMINO ACID ANTICONVULSANTS SLC1A2, SLC1A1, SLC1A3 HDAC1 1427/4885HDAC6 900/4885GAA 2331/4885
US-20100260716-A1 COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS PMP22, MAG, MYT1 HDAC1 165/4885HDAC6 94/4885GAA 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.